341 Allerton Ave
South San Francisco
4 articles about Cellares
Cellares and Cabaletta Bio Partner to Evaluate Automated Manufacturing for CABA-201, Cabaletta’s CD19-CAR T Cell Therapy on Cellares’ Cell Shuttle Platform
Cellares and Cabaletta Bio, Inc. today announced Cabaletta will evaluate Cellares’ automated manufacturing platform, the Cell Shuttle™, through Cellares’ Technology Adoption Partnership (TAP) program.
Cellares Announces Expanded Agreement with Bristol Myers Squibb to Include Second CAR-T Program in Cellares’ Technology Adoption Partnership Program
Cellares, the first Integrated Development and Manufacturing Organization dedicated to clinical and industrial-scale cell therapy manufacturing, announced that global biopharmaceutical company and cell therapy leader Bristol Myers Squibb will enter a second proof-of-concept tech transfer process for the manufacture of a CAR-T cell therapy, as part of the Cellares Technology Adoption Partnership program.
Cellares and Lyell to Evaluate Automated Manufacturing of Lyell’s CAR T-Cell Therapy on Cellares’ Cell Shuttle Platform
Cellares and Lyell Immunopharma announced Lyell will evaluate Cellares’ automated manufacturing platform, the Cell Shuttle™, through Cellares’ Technology Adoption Partnership program.
Cellares, a biotech company dedicated to making life-saving cell therapies accessible and affordable to patients in need, announced the appointment of Arturo Araya as its new EVP of Commercialization.